Clinical trials: Male Pattern Baldness
Alopecia, Androgenetic
Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia
The purpose of this study is to confirm the clinical efficacy and the safety of P-3074 in participants with androgenetic alopecia.
- Trial name
- NCT03004469
- Testing
- P-3074, Finasteride, P-3074 Vehicle
- Where
- 46 sites in Belgium, Germany and 3 more
- Volunteers
- 458 people
- Sponsor
- Polichem S.A.
Female Pattern Baldness, Alopecia, Androgenetic
Hairstetics™ Anchoring System in Female Pattern Hair Loss (HAS-FPHL)
The aim of the study is to provide evidence of safety and preliminary performance of the Hairstetics™ anchoring system in female subjects affected with androgenetic alopecia (female pattern hair loss; (FPHL)).
- Trial name
- HAS-FPHL (NCT02316418)
- Testing
- Hairstetics™ anchoring system
- Where
- India
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Hairstetics
Androgenetic Alopecia
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia.
- Trial name
- NCT01231607
- Testing
- 1mg Finasteride active, 0.02mg dutasteride, 0.1mg dutasteride
- Where
- 39 sites in Argentina, Chile and 7 more
- Volunteers
- 917 people
- Sponsor
- GlaxoSmithKline
Hair Loss, Hair Loss/Baldness
HairDx Analytical Validation Study
The HairDx Test reports genetic variants associated with the development of FPHL.
- Conditions
- Hair Loss, Hair Loss/Baldness, Female Pattern Baldness, Androgenetic Alopecia
- Trial name
- NCT04379583
- Testing
- HairDx Sample Collection Kit
- Where
- United States
- Sponsor
- Applied Biology, Inc.
Androgenetic Alopecia
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia
- Trial name
- NCT06916793
- Testing
- CKD-843 dose#1, CKD-843 dose#2, Dutasteride Capsules
- Where
- South Korea
- Volunteers
- 288 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931)
Evaluate the ability of injections of Ji Gami(TM) CN to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01669746
- Testing
- Autologous cultured mixed population of dermal cells
- Where
- 7 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Alopecia, Androgenetic
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and safe and how well the drug is tolerated by subjects.
- Trial name
- SCALP1 (NCT05910450)
- Testing
- Clascoterone 5% solution, Vehicle solution
- Where
- 24 sites in United States, Georgia
- Volunteers
- 703 people
- Sponsor
- Cassiopea SpA
Androgenetic Alopecia, Hair Loss
Treatment of Androgenetic Alopecia in Females, 9 Beam
The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 9 beam model in promoting hair growth in females diagnosed with androgenetic alopecia when treatment is applied as directed.
- Conditions
- Androgenetic Alopecia, Hair Loss, Female Pattern Baldness
- Trial name
- NCT00981461
- Testing
- HairMax LaserComb, Control Device
- Where
- 5 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013)
The purpose of the study is to evaluate the ability of injections Ji Gami(TM) to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451073
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 6 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia
Minoxidil Response Testing in Males With Androgenetic Alopecia
Topical minoxidil is the most common drug used for the treatment of AGA in men. While topical minoxidil exhibits a good safety profile, the efficacy in the overall population remains relatively low i.e., 30-40% re-grow hair.
- Trial name
- NCT02198261
- Testing
- 5% minoxidil topical foam
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 300 people
- Sponsor
- Applied Biology, Inc.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)
The purpose of this study is to evaluate the ability of injections of Ji Gami(TM) N and Ji Gami(TM) NDO to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451138
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia, AGA
Efficacy and Safety of VDPHL01 in Males With AGA
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to…
- Conditions
- Androgenetic Alopecia, AGA, Male Pattern Baldness
- Trial name
- NCT06724614
- Testing
- VDPHL01
- Where
- 44 sites in United States
- Volunteers
- 480 people
- Sponsor
- Veradermics, Inc.
Androgenetic Alopecia
the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending
The study is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability and PK of KX-826 following topical multiple ascending dose administration.
- Trial name
- NCT04502901
- Testing
- KX0826
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea, Hypersexuality in Men
A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe
Androcur is a type of treatment called cyproterone acetate (CPA). Androcur and other CPA treatments work by blocking a group of male sex hormones called androgens in the body.
- Conditions
- Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea, Hypersexuality in Men, Sexual Deviations in Men, Prostate Cancer
- Trial name
- Safe-CAM (NCT04925180)
- Testing
- Cyproterone Acetate (Androcur, BAY94-8367)
- Where
- 5 sites in France, Germany and 3 more
- Volunteers
- 600 people
- Sponsor
- Bayer
Androgenetic Alopecia
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).
- Trial name
- NCT02275351
- Testing
- Topical SM04554 solution, Topical vehicle solution
- Where
- 24 sites in United States
- Volunteers
- 302 people
- Sponsor
- Biosplice Therapeutics, Inc.
Androgenetic Alopecia
Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
The purpose of this study is to measure the hair growth response to topical NEOSH101 when applied twice daily to the balding scalp for 16 weeks.
- Trial name
- NCT00418730
- Testing
- tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
- Where
- Germany
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Neosil, Inc.
Androgenetic Alopecia
Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss
HCap Formula is composed of medicinal plants, vitamins and minerals. The purpose of this study is to evaluate the efficacy of HCap Formula, a nutrition supplement for promoting hair growth in men with tendencies for hair loss.
- Trial name
- NCT02150187
- Testing
- HCap Formula
- Where
- Israel
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Family Marketing
Androgenetic Alopecia
A Study to Evaluate the Efficacy and Safety of AD-208
The purpose of this study is to evaluate the efficacy and safety of AD-208.
- Trial name
- NCT04825561
- Testing
- AD-208, AD-2081
- Where
- South Korea
- Volunteers
- 139 people
- Sponsor
- Addpharma Inc.
Female Pattern Baldness, Hair Loss
ENERGI-F701 for Female Hair Loss Treatment
The objective of this study is to evaluate the efficacy and safety of ENERGI-F701 Solution in female subjects with hair loss.
- Conditions
- Female Pattern Baldness, Hair Loss, Alopecia
- Trial name
- NCT03351322
- Testing
- ENERGI-F701, Regaine
- Where
- Taiwan
- Volunteers
- 67 people
- Sponsor
- Energenesis Biomedical Co., Ltd.
Androgenetic Alopecia
A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia
To investigate the efficacy of HMI-115 compared to placebo in treating Androgenic Alopecia patients for 24 weeks
- Trial name
- NCT06118866
- Testing
- HMI-115-120mg-Q4W, HMI-115-240mg-Q4W, HMI-115, 240mg-Q2W
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Hope Medicine (Nanjing) Co., Ltd